ONCOCYTIC ISOCITRATE DEHYDROGENASE MUTATIONS: MECHANISMS, MODELS, AND CLINICAL OPPORTUNITIES............ 730
R.A. Cairns and T.W. Mak

DISCOVERY OF A NOVEL ERK INHIBITOR WITH ACTIVITY IN MODELS OF ACQUIRED RESISTANCE TO BRAF AND MEK INHIBITORS.............. 742
Précis: An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells. See commentary, p. 719

INHIBITION OF RON KINASE BLOCKS CONVERSION OF MICROMETASTASES TO OVERT METASTASES BY BOOSTING ANTITUMOR IMMUNITY.............. 751
H. Eyob, H.A. Ekiz, Y.S. DeRose, S.E. Waltz, M.A. Williams, and A.L. Welm
Précis: The receptor tyrosine kinase RON suppresses antitumor immune responses to promote metastatic outgrowth and is a potential therapeutic target to inhibit metastasis.

FREQUENT MUTATION OF THE PI3K PATHWAY IN HEAD AND NECK CANCER DEFINES PREDICTIVE BIOMARKERS ... 761
Précis: PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors. See commentary, p. 722

NOT EXPECTING THE UNEXPECTED: DIACYLGLYCEROL KINASE ALPHA AS A CANCER TARGET.......................... 726
K.P.L. Bhat and K. Aldape
See article, p. 782

EXPLOITING THE HEAD AND NECK CANCER ONCOGENOME: WIDESPREAD PI3K-mTOR PATHWAY ALTERATIONS AND NOVEL MOLECULAR TARGETS ...... 722
R. Iglesias-Bartolome, D. Martin, and J.S. Gutkind
See article, p. 761
See article, p. 770

ERK PATHWAY INHIBITORS: HOW LOW SHOULD WE GO? ......... 719
M.H. Nissan, N. Rosen, and D.B. Solit
See article, p. 742

IN THE SPOTLIGHT

Q&A: Suzanne Topalian on Immune Therapies .......... 712
A Look at the Origins of Cancer Epigenetics .......... 713

IMPORTED FROM CANCER DISCOVERY ONLINE AT HTTP://CDNEWS.AACRJOURNALS.ORG
Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers .......... 770
Précis: Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.
See commentary, p. 722

Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers .......... 782
Précis: Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.
See commentary, p. 726

ZNF365 Promotes Stability of Fragile Sites and Telomeres .......... 798
Précis: ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention .......... 812
Précis: SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.
See commentary, p. 728